Data shown is for informational purposes only and does not constitute investment advice. TopFund is not SEBI-registered. Consult a SEBI-registered advisor before investing.
Anlon Healthcare IPO
Price Band
₹86.0–91.0
Issue Size
₹121.03 Cr
Lot Size
164 shares
Min Investment
₹14,924
GMP
+₹1.0 (1.1%)
Issue Price
₹91.0
Subject to Sauda
₹100
Paid only if allotted
Anlon Healthcare IPO AI Summary
- Anlon Healthcare IPO is listed on BSE, NSE in the Pharmaceuticals sector.
- Price band: ₹86.0–₹91.0 per share, lot size 164 shares (min. investment ₹14,924).
- Subscription window: 26 Aug–29 Aug 2025, listing on 03 Sep 2025.
- Current GMP is +₹1.0 (1.1%), an estimated listing price of ₹92 — unofficial and can change daily.
Anlon Healthcare Limited is a pharmaceutical manufacturing company with a focus on high-purity intermediates and APIs. The company has shown a recovery in revenue and consistent profit growth, with a well-defined plan for the use of IPO proceeds. Investors should consider their risk tolerance and investment strategy when evaluating this IPO.
TopFund is not SEBI-registered — this is educational analysis, not personalized investment advice.
Anlon Healthcare IPO — Third-Party Research Views
Reviews below reflect analyst calls made before this IPO closed on 29 Aug 2025 — not a current signal.
2 of 2 reviewers say Neutral
Recommendations are sourced from third-party research firms and are not TopFund's own investment advice.
Important Dates
Subscription Status
Subscription data unavailable
Anlon Healthcare IPO Grey Market Premium (GMP) Today
GMP
+₹1.0
GMP %
+1.1%
Est. Listing
₹92.0
Updated: 25 Jul 2026 14:13
About the Company
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs). The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products). The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP. In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs. The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals. The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards. The company's product portfolio consists of sixty-five (65) commercialised products and twenty-eight (28) products at pilot stage and forty-nine (49) products at laboratory testing stage/ laboratory scale stage. Products: Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs. Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products. Competitive Strengths: Strong product portfolio and scalable business. Strong Promoters and Experienced Management Team. High entry and exit barriers due to long customer approval cycles and strict product standards. In-house Testing, Quality Control and Quality Assurance for quality control. Focus on Quality, Environment, Health and Safety.
Company Financials (₹ Cr)
As of 2025-03-31
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 181.30 | 128.00 | 111.55 |
| Total Income | 120.46 | 66.69 | 113.12 |
| Profit After Tax | 20.52 | 9.66 | 5.82 |
| EBITDA | 32.38 | 15.57 | 12.66 |
| NET Worth | 80.42 | 21.03 | 7.37 |
| Reserves and Surplus | 40.57 | 5.03 | -4.63 |
| Total Borrowing | 58.35 | 74.56 | 66.39 |
Key Ratios
EPS
₹5.15
NAV
₹20.18
ROE
40.45%
ROCE
21.93%
RoNW
25.51%
P/B Value
4.51
P/E Ratio
17.67
Market Cap
₹483.68 Cr
PAT Margin
17.06%
Debt/Equity
0.73
Peer Comparison
| Company | NAV | RoNW | P/E (x) | EPS Basic | EPS Diluted |
|---|---|---|---|---|---|
| Supriya Lifeciences | 123.85 | 18.86% | 29.27 | 23.35 | 23.35 |
| Acutaas Chemicals | 161.24 | 12.15% | 58.47 | 19.81 | 19.81 |
| Kronox Lab Sciences | 24.28 | 28.26% | 26.18 | 6.91 | 6.91 |
| Anlon Healthcare This IPO | 20.18 | 25.51% | — | 6.38 | 6.38 |
Promoters
Punitkumar R.rasadia, Meet Atulkumar Vachhani and Mamata punitkumar Rasadia
Objects of the Issue
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects: # Issue Objects Est Amt (₹ Cr.) 1 Funding capital expenditure requirements for Proposed Expansion 30.72 2 Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company 5.00 3 Funding the working capital requirements of the Company 43.15 4 General Corporate Purposes 27.03 5 Issue Expenses 15.13 Total 121.03
IPO Evaluation
Generated 23 Sep 2026Revenue Trend
Total income was ₹113.12 Cr in the year ending 31 Mar 2023, which decreased to ₹66.69 Cr by 31 Mar 2024. However, it rebounded to ₹120.46 Cr by 31 Mar 2025. This indicates a recovery in revenue after a decline in the previous year.
Profit Trend
Profit After Tax was ₹5.82 Cr in the year ending 31 Mar 2023, increasing to ₹9.66 Cr by 31 Mar 2024. By 31 Mar 2025, it further rose to ₹20.52 Cr. This shows a consistent upward trend in profitability over the periods analyzed.
Valuation
Anlon Healthcare has an implied P/E of 17.67 at the issue price, compared to peers trading at a P/E range of approximately 26.18 to 58.47.
Grey Market Premium, Explained
The Grey Market Premium (GMP) indicates the expected listing price of an IPO compared to its issue price. A positive GMP suggests that the stock may list at a higher price than its issue price, reflecting demand in the unofficial market.
Who This IPO Suits
Investors comfortable with short-term volatility and a long-term horizon typically weigh IPOs like this against their investment strategy, market conditions, and the company's growth potential.
Who May Want to Wait
Investors with a low-risk tolerance or those seeking stable, dividend-paying investments may want to avoid IPOs like this, which can be more volatile.
Listing Gains — The Risk
Listing-day gains can be uncertain and depend on market conditions, investor sentiment, and overall demand for the stock. It is important to consider the long-term potential of the company rather than focusing solely on short-term listing gains.
This evaluation is generated from Anlon Healthcare's own public IPO filing data for educational purposes and is not investment advice or a recommendation to apply, subscribe to, or avoid this issue — see Broker Recommendations below for named third-party research views (clearly attributed, not TopFund's own). TopFund is not a SEBI-registered investment adviser — see our Disclaimer.
Frequently Asked Questions
What is Anlon Healthcare IPO GMP today?
Anlon Healthcare IPO GMP today is +₹1.0 (1.1%), indicating an estimated listing price of ₹92. GMP is an unofficial grey-market indicator and can change daily.
What is the price band of Anlon Healthcare IPO?
The price band of Anlon Healthcare IPO is ₹86.0–₹91.0 per share.
When does Anlon Healthcare IPO open and close?
Anlon Healthcare IPO opens on 26 August 2025 and closes on 29 August 2025.
When does Anlon Healthcare IPO list on the stock exchange?
Anlon Healthcare IPO listed on 03 September 2025 at ₹92.0.
What is the lot size for Anlon Healthcare IPO?
The lot size for Anlon Healthcare IPO is 164 shares, requiring a minimum investment of ₹14,924.
What is the lot size for the Anlon Healthcare IPO?
The lot size for the Anlon Healthcare IPO is 164 shares.
What is the minimum investment required?
The minimum investment required is ₹14,924.
What is the price band for the IPO?
The price band for the IPO is ₹86.0 to ₹91.0.
When is the listing date for the IPO?
The listing date for the IPO is 3rd September 2025.
What does GMP mean?
GMP stands for Grey Market Premium, which indicates the expected premium at which the stock may list compared to its issue price.
Issue Details
Investor Allocation
Registrar
Lead Managers / Book Running
IPO Timeline
Open
26 Aug 2025
Close
29 Aug 2025
Allotment
01 Sep 2025
Listing
03 Sep 2025
Similar IPOs in Pharmaceuticals
Plan Your IPO Investment
Related Articles
Community Sentiment
What are other investors planning for Anlon Healthcare?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
No comments yet — start the discussion.